$50M raised to advance brain stimulation device

Inbrain Neuroelectronics has raised $50 million in Series B funding to advance its brain-computer interface (BCI) technology for personalized neurological treatments, particularly for Parkinson’s disease. Utilizing ultra-thin graphene electrodes, Inbrain’s BCI aims to deliver precise, adaptive neural stimulation based on real-time brain activity, enhancing treatment outcomes while reducing side effects. The company’s graphene-based electrodes—thinner than a human hair—continuously record and analyze brain signals using an AI-driven platform to tailor stimulation precisely when needed. This approach is designed to improve on existing deep brain stimulation (DBS) devices, which deliver consistent electrical pulses regardless of symptom changes. In addition to the funding, Inbrain secured support from pharmaceutical giant Merck KGaA to explore applications in its therapeutic focus areas. The platform, designated a breakthrough device by the FDA, is also being tested for other neurological conditions, including epilepsy, stroke recovery, and brain cancer. A recent clinical trial at Salford Royal Hospital in the U.K. demonstrated its ability to differentiate between healthy and cancerous brain tissue with high precision. In collaboration with digital technology firm Imec, Inbrain aims to scale graphene production for broader commercial applications. The funding will support ongoing clinical trials and further development, with the goal of transforming neurological treatments through more intelligent, adaptable neurotechnology. (Photo Credit: INBRAIN Neuroelectronics)